Hybrid compounds: From simple combinations to nanomachines

被引：45
作者：
Andreas Müller-Schiffmann
Heinrich Sticht
Carsten Korth
机构：
[1] Department of Neuropathology, Heinrich Heine University Dsseldorf, Heinrich Heine University Medical School, 40225 Dsseldorf
[2] Institute for Biochemistry, University of Erlangen-Nrnberg, Erlangen
来源：
BioDrugs | 2012年 / 26卷 / 1期
基金：
欧盟第七框架计划;
关键词：
Biotechnology; Conjugates; Multiprotein-complex-targets; Nanoparticles; Research-and-development;
D O I：
10.2165/11597630-000000000-00000
中图分类号：
学科分类号：
摘要：
The combination of two different and independently acting compounds into one covalently linked hybrid compound can convey synergy from the effects of both independently acting moieties to the new composite compound, leading to a pharmacological potency greater than the sum of each individual moietys potencies.Here, we review a variety of such hybrid compounds, which can consist of various functional parts, molecular recognition or subcellular targeting moieties, or combinations thereof, acting either simultaneously or sequentially. Such moieties within a hybrid compound can consist of a variety of substance classes, including small organic molecules, polypeptides or nucleic acids identified either via rational molecular design or selection from libraries.Precedent for hybrid compounds comes from naturally occurring proteins and small molecules, such as botulinum toxin and bleomycin, which are secreted by micro-organisms. We review the high degree of suitability of hybrid compounds for the treatment of multifactorial diseases by simultaneously hitting several targets along an identified disease pathway. Examples are hybrid compounds against Alzheimers disease, against the cancer-relevant phosphoinisitide-3- kinase (PI3K)AKTmammalian target of rapamycin (mTOR) and epidermal growth factor signaling cascade, or in antimalarial therapy via simultaneous hitting of different mechanisms of hemozoin formation. Molecular recognition by peptides or aptamers (recognition-specific RNA or peptide sequences) can be combined with the transport of small molecule β-sheet breakers or toxins, or targeting to ubiquitin-dependent proteolysis. The vision of molecular nanomachines is currently realized in sequentially acting modular nanotransporters, consisting of four modules including a target, a membrane and nuclear translocation sequence, as well as a drug attachment domain.Through the rational combination of existing drugs and the synergy of their effects, a rapid amplification of their potency may be achieved, greatly accelerating drug development. A further enhancement of simultaneous multitarget action is enabled through the design of multifunctional hybrid drugs with sequential effects that make these hybrid molecules resemble intelligent nanomachines. © 2012 Adis Data Information BV. All rights reserved.
引用
收藏
页码：21 / 31
页数：10
相关论文
共 62 条
[21]  
Ayral-Kaloustian S., Gu J., Lucas J., Et al., Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): Design, synthesis, and superior antitumor activity of novel wortmanninrapamycin conjugates, J Med Chem, 53, 1, pp. 452-9, (2010)
[22]  
Meric-Bernstam F., Gonzalez-Angulo A.M., Targeting the mTOR signaling network for cancer therapy, J Clin Oncol, 27, 13, pp. 2278-87, (2009)
[23]  
Liang J., Choi J., Clardy J., Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution, Acta Crystallographica Section D: Biological Crystallography, 55, 4, pp. 736-744, (1999)
[24]  
Walker E.H., Pacold M.E., Perisic O., Et al., Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine, Mol Cell, 6, 4, pp. 909-19, (2000)
[25]  
Cai X., Zhai H.X., Wang J., Et al., Discovery of 7- (4- (3-ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)- N-hydroxyheptanam ide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer, J Med Chem, 53, 5, pp. 2000-9, (2010)
[26]  
Lai C.J., Bao R., Tao X., Et al., CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity, Cancer Res, 70, 9, pp. 3647-56, (2010)
[27]  
Muregi F.W., Kirira P.G., Ishih A., Novel rational drug design strategies with potential to revolutionize malaria chemotherapy, Curr Med Chem, 18, 1, pp. 113-43, (2011)
[28]  
Loup C., Lelievre J., Benoit-Vical F., Meunier B., Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine, Antimicrobial Agents and Chemotherapy, 51, 10, pp. 3768-3770, (2007)
[29]  
Singh Y., Palombo M., Sinko P.J., Recent trends in targeted anticancer prodrug and conjugate design, Curr Med Chem, 15, 18, pp. 1802-26, (2008)
[30]  
Kohno M., Horibe T., Haramoto M., Et al., A novel hybrid peptide targeting EGFR-expressing cancers, Eur J Cancer, 47, pp. 773-83, (2010)
1234567